621 related articles for article (PubMed ID: 27528374)
1. Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis.
Howse PM; Chibrikova LN; Twells LK; Barrett BJ; Gamble JM
Am J Kidney Dis; 2016 Nov; 68(5):733-742. PubMed ID: 27528374
[TBL] [Abstract][Full Text] [Related]
2. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
Cornell S
J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
[TBL] [Abstract][Full Text] [Related]
3. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.
Campbell RK
Clin Ther; 2011 May; 33(5):511-27. PubMed ID: 21665040
[TBL] [Abstract][Full Text] [Related]
4. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
[TBL] [Abstract][Full Text] [Related]
5. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.
Li L; Shen J; Bala MM; Busse JW; Ebrahim S; Vandvik PO; Rios LP; Malaga G; Wong E; Sohani Z; Guyatt GH; Sun X
BMJ; 2014 Apr; 348():g2366. PubMed ID: 24736555
[TBL] [Abstract][Full Text] [Related]
6. Comparison of efficacy and safety of three novel hypoglycemic agents in patients with severe diabetic kidney disease: A systematic review and network meta-analysis of randomized controlled trials.
Li Y; Hu Y; Huyan X; Chen K; Li B; Gu W; Mu Y
Front Endocrinol (Lausanne); 2022; 13():1003263. PubMed ID: 36353233
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
Amori RE; Lau J; Pittas AG
JAMA; 2007 Jul; 298(2):194-206. PubMed ID: 17622601
[TBL] [Abstract][Full Text] [Related]
8. The effects of incretin-based therapies on β-cell function and insulin resistance in type 2 diabetes: A systematic review and network meta-analysis combining 360 trials.
Wu S; Gao L; Cipriani A; Huang Y; Yang Z; Yang J; Yu S; Zhang Y; Chai S; Zhang Z; Sun F; Zhan S
Diabetes Obes Metab; 2019 Apr; 21(4):975-983. PubMed ID: 30536884
[TBL] [Abstract][Full Text] [Related]
9. Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Wang H; Liu Y; Tian Q; Yang J; Lu R; Zhan S; Haukka J; Hong T
Diabetes Obes Metab; 2018 Apr; 20(4):910-920. PubMed ID: 29193572
[TBL] [Abstract][Full Text] [Related]
10. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis.
Liu J; Li L; Deng K; Xu C; Busse JW; Vandvik PO; Li S; Guyatt GH; Sun X
BMJ; 2017 Jun; 357():j2499. PubMed ID: 28596247
[No Abstract] [Full Text] [Related]
11. Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.
Scheen AJ
Clin Pharmacokinet; 2015 Jan; 54(1):1-21. PubMed ID: 25331711
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: A systematic review and network meta-analysis of randomized controlled trials.
Yang Q; Lang Y; Yang W; Yang F; Yang J; Wu Y; Xiao X; Qin C; Zou Y; Zhao Y; Kang D; Liu F
Diabetes Res Clin Pract; 2023 Apr; 198():110592. PubMed ID: 36842477
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review.
Aroda VR; Henry RR; Han J; Huang W; DeYoung MB; Darsow T; Hoogwerf BJ
Clin Ther; 2012 Jun; 34(6):1247-1258.e22. PubMed ID: 22608780
[TBL] [Abstract][Full Text] [Related]
14. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
Sloan LA
J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.
Yamada T; Wakabayashi M; Bhalla A; Chopra N; Miyashita H; Mikami T; Ueyama H; Fujisaki T; Saigusa Y; Yamaji T; Azushima K; Urate S; Suzuki T; Abe E; Wakui H; Tamura K
Cardiovasc Diabetol; 2021 Jan; 20(1):14. PubMed ID: 33413348
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl Peptidase-4 Inhibitors in Chronic Kidney Disease: A Systematic Review of Randomized Clinical Trials.
Walker SR; Komenda P; Khojah S; Al-Tuwaijri W; MacDonald K; Hiebert B; Tangri N; Nadurak SWD; Ferguson TW; Rigatto C; Tangri N
Nephron; 2017; 136(2):85-94. PubMed ID: 28178698
[TBL] [Abstract][Full Text] [Related]
17. Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis.
Waldrop G; Zhong J; Peters M; Goud A; Chen YH; Davis SN; Mukherjee B; Rajagopalan S
J Diabetes Complications; 2018 Jan; 32(1):113-122. PubMed ID: 29074120
[TBL] [Abstract][Full Text] [Related]
18. The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis.
Wu S; Cipriani A; Yang Z; Yang J; Cai T; Xu Y; Quan X; Zhang Y; Chai S; Sun F; Zhan S
Expert Opin Drug Saf; 2018 Mar; 17(3):243-249. PubMed ID: 29320889
[TBL] [Abstract][Full Text] [Related]
19. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
[TBL] [Abstract][Full Text] [Related]
20. Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.
Dejager S; Schweizer A
Hosp Pract (1995); 2012 Apr; 40(2):7-21. PubMed ID: 22615074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
